• 21Feb
    Written By Lars Haakon Soraas

    Week 26 in the war on cancer. It has been half a year since we started regarding this fight as a war. A war that we are determined to win.
    Here are the highlights of the past week:
    -Dyanne started Tagrisso (aka AZD9291 aka osimertinib) on Monday this week. The drug is tailormade for patients who have taken erlotinib and then gotten resistant to erlotinib due to a mutation called T790M. The drug is a so-called "targeted therapy", meaning that it targets this specific mutation. Studies done show that it gives patients with brain metastasis a median progress free survival (PFS) of 8 months. We got half the median PFS on erlotinib, but hope to be luckier this time.

  • 14Feb
    Written By Lars Haakon Soraas

    Week 25 in the war on cancer. Or, more specifically, in the war against Dyanne's version of EGFR positive lung cancer. Here are the highlights:
    -We learned this week that the application to get Tagrisso (aka AZD9291 aka osimertinib) has been approved. We will get the drug tomorrow and Dyanne will start on it then. Getting this drug on compassionate use was our best case scenario. First of all we are grateful to get it at all, and secondly, getting it on compassionate use means we are free to combine with other types of treatment that may help. If we only got it on a trial, it would have been difficult to do some of the other treatment we are doing and planning.

Follow this blog

Get every new post delivered right to your inbox.